Daraxonrasib Shows 90% Disease Control in Pancreatic Cancer Trial, With 30% Tumor Response
Updated
Updated · Fox News · May 18
Daraxonrasib Shows 90% Disease Control in Pancreatic Cancer Trial, With 30% Tumor Response
6 articles · Updated · Fox News · May 18
168 patients with advanced pancreatic cancer carrying RAS mutations received daraxonrasib in a first-in-human phase 1/2 trial, and about 90% saw their disease shrink or stop worsening.
At the 300-mg dose planned for phase 3 testing, roughly 30% had a confirmed response, suggesting the daily pill may work broadly in a cancer where more than 90% of tumors carry RAS-related mutations.
Rash, mouth inflammation, nausea and diarrhea were the most common side effects, but researchers said most patients stayed on treatment and few stopped because of toxicity.
Dana-Farber investigators said the study, published in The New England Journal of Medicine, does not prove the drug beats chemotherapy because it lacked a randomized control arm and enrolled only previously treated patients.
Outside experts called the results potentially practice-changing, but fuller efficacy and safety data are still awaited at ASCO later this month and in larger trials.
A new pill doubles pancreatic cancer survival. Is this a cure, or just the most expensive hope yet?
The 'undruggable' cancer gene has been hit. What happens when tumors learn to fight back against this new drug?
A breakthrough drug is available before full approval. Who decides which patients get early access to a longer life?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: Breakthrough Therapy Nears FDA Approval
Overview
Pancreatic cancer is a devastating and aggressive disease, with many patients dying within months of diagnosis and a five-year survival rate of just 3% for those with metastatic disease. Each year, over 50,000 Americans lose their lives to this cancer, which accounts for about 8% of all cancer deaths in the United States. Current treatments often provide limited benefits, highlighting the urgent need for better options. This challenging prognosis underscores the importance of recent breakthroughs that aim to improve survival and offer new hope for patients facing this difficult diagnosis.